Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients [Yahoo! Finance]
Palisade Bio, Inc. (PALI)
Company Research
Source: Yahoo! Finance
The findings highlight that this once-daily oral prodrug, designed for targeted delivery to the terminal ileum and colon, achieved localized target engagement and clinical response within 7 days in patients with moderate-to-severe ulcerative colitis. The data showed a 100% clinical response rate and a 40% clinical remission rate based on modified Mayo Scores, supported by a safety profile across 89 total subjects with no serious adverse events or treatment discontinuations. Mechanism-of-action data derived from colon tissue RNA sequencing confirmed that PALI-2108 successfully suppresses inflammatory and fibrotic gene programs. The results were accompanied by reduced mucosal PDE4B expression, increased tissue cAMP levels, and decreased inflammatory cell signatures. These pharmacologic effects were concentrated in the colonic tissue, while peripheral immune profiles remained largely unchanged, validating the drug's localized activity. Palisade Bio (PALI) Reports Positive Phase 1b Da
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Announces Participation in Two Upcoming Investor ConferencesGlobeNewswire
- Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026GlobeNewswire
- Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory BoardGlobeNewswire
- Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium [Yahoo! Finance]Yahoo! Finance
PALI
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- PALI's page on the SEC website